Celltrion said Remsima, its infliximab biosimilar, became Japan’s most-prescribed infliximab product with a 48% market share as of July, according to IQVIA and local data. It overtook the originator drug among four infliximab products sold in Japan, about 11 years after its April 2015 launch. Because out-of-pocket cost differences between originator medicines and biosimilars are relatively small in Japan, Celltrion has relied on clinical and prescription data, brand strength, and sales capabilities, including a two-track strategy with Nippon Kayaku and its own Japanese subsidiary. Celltrion sells four autoimmune treatments in Japan, with Yuflyma holding a 21% share among adalimumab biosimilars and Aptozma recording about 10% based on its intravenous formulation. Oncology products Herzuma and Vegzelma held 78% and 64% shares, respectively, giving Celltrion three category-leading products in Japan. The company is preparing a 2027 launch for Remsima SC. Remsima generated about 1.0495 trillion won ($759.0 million) in global sales last year, exceeding 1 trillion won for a second consecutive year.